N-3 polyunsaturated fatty acids: An innovative strategy against obesity and related metabolic disorders, intestinal alteration and gut microbiota dysbiosis.


Journal

Biochimie
ISSN: 1638-6183
Titre abrégé: Biochimie
Pays: France
ID NLM: 1264604

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 11 12 2018
accepted: 22 01 2019
pubmed: 29 1 2019
medline: 4 4 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

Obesity is now widely recognized to be associated with low-grade systemic inflammation. It has been shown that high-fat feeding modulates gut microbiota which strongly increased intestinal permeability leading to lipopolysaccharide absorption causing metabolic endotoxemia that triggers inflammation and metabolic disorders. N-3 polyunsaturated fatty acids (PUFAs) have been shown associated with anti-obesity properties, but results still remain heterogeneous and very few studies underlined the metabolic pathways involved. Thus, the use of Fat-1 transgenic mice allows to better understanding whether endogenous n-3 PUFAs enrichment contributes to obesity and associated metabolic disorders prevention. It specially evidence that such effects occur through modulations of gut microbiota and intestinal permeability. Then, by remodeling gut microbiota, endogenous n-3 PUFAs improve HF/HS-diet induced features of the metabolic syndrome which in turn affects host metabolism. Thus, increasing anti-obesogenic microbial species in the gut microbiota population (i.e Akkermansia) by appropriate n-3 PUFAs may represent a promising strategy to control or prevent metabolic diseases.

Identifiants

pubmed: 30690133
pii: S0300-9084(19)30025-2
doi: 10.1016/j.biochi.2019.01.017
pii:
doi:

Substances chimiques

Fatty Acids, Omega-3 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

66-71

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Jérôme Bellenger (J)

Université de Bourgogne Franche-Comté, UFR Sciences de la Vie, de la Terre et de l'Environnement, Lipides Nutrition Cancer UMR UMR1231, 6 Boulevard Gabriel, 21000, Dijon, France; INSERM, Lipides Nutrition Cancer UMR1231, 21000, Dijon, France; LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, 21000, Dijon, France. Electronic address: jerome.bellenger@u-bourgogne.fr.

Sandrine Bellenger (S)

Université de Bourgogne Franche-Comté, UFR Sciences de la Vie, de la Terre et de l'Environnement, Lipides Nutrition Cancer UMR UMR1231, 6 Boulevard Gabriel, 21000, Dijon, France; INSERM, Lipides Nutrition Cancer UMR1231, 21000, Dijon, France; LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, 21000, Dijon, France.

Quentin Escoula (Q)

Université de Bourgogne Franche-Comté, UFR Sciences de la Vie, de la Terre et de l'Environnement, Lipides Nutrition Cancer UMR UMR1231, 6 Boulevard Gabriel, 21000, Dijon, France; INSERM, Lipides Nutrition Cancer UMR1231, 21000, Dijon, France; LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, 21000, Dijon, France; Valorex, La Messayais, 35210, Combourtillé, France.

Célia Bidu (C)

Université de Bourgogne Franche-Comté, UFR Sciences de la Vie, de la Terre et de l'Environnement, Lipides Nutrition Cancer UMR UMR1231, 6 Boulevard Gabriel, 21000, Dijon, France; INSERM, Lipides Nutrition Cancer UMR1231, 21000, Dijon, France; LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, 21000, Dijon, France.

Michel Narce (M)

Université de Bourgogne Franche-Comté, UFR Sciences de la Vie, de la Terre et de l'Environnement, Lipides Nutrition Cancer UMR UMR1231, 6 Boulevard Gabriel, 21000, Dijon, France; INSERM, Lipides Nutrition Cancer UMR1231, 21000, Dijon, France; LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, 21000, Dijon, France. Electronic address: michel.narce@u-bourgogne.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH